Application 211479
- Type
- ANDA
- Sponsor
- MSN LABS PVT LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DAPAGLIFLOZIN | METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE; ORAL | 5MG; 500MG | No | No |
| 002 | DAPAGLIFLOZIN | METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE; ORAL | 5MG; 1GM | No | No |
| 003 | DAPAGLIFLOZIN | METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE; ORAL | 10MG; 500MG | No | No |
| 004 | DAPAGLIFLOZIN | METFORMIN HYDROCHLORIDE | TABLET, EXTENDED RELEASE; ORAL | 10MG; 1GM | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211479-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | |
| A211479-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | |
| A211479-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | |
| A211479-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211479-001 | AB |
| A211479-002 | AB |
| A211479-003 | AB |
| A211479-004 | AB |
Orange Book exclusivity#
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| A211479-001 | PC | 2026-10-03 |
| A211479-002 | PC | 2026-10-03 |
| A211479-003 | PC | 2026-10-03 |
| A211479-004 | PC | 2026-10-03 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211479-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A211479-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A211479-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A211479-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A211479-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211479-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211479-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A211479-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A211479-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211479-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211479-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A211479-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A211479-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211479-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211479-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A211479-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-001 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-002 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 5MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-003 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;500MG | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-004 | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | 10MG;1GM | TABLET, EXTENDED RELEASE / ORAL | AB | 2026-04-06 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211479-001 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211479-002 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211479-003 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211479-004 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-002 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-003 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-004 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-002 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-003 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-004 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-002 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-003 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-004 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-002 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-003 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-004 | AB | 1 | a50c72e98297… |
Observed Orange Book exclusivity history#
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A211479-001 | PC | 2026-10-03 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211479-002 | PC | 2026-10-03 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211479-003 | PC | 2026-10-03 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A211479-004 | PC | 2026-10-03 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-001 | PC | 2026-10-03 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-002 | PC | 2026-10-03 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-003 | PC | 2026-10-03 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A211479-004 | PC | 2026-10-03 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-001 | PC | 2026-10-03 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-002 | PC | 2026-10-03 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-003 | PC | 2026-10-03 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A211479-004 | PC | 2026-10-03 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-001 | PC | 2026-10-03 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-002 | PC | 2026-10-03 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-003 | PC | 2026-10-03 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A211479-004 | PC | 2026-10-03 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-001 | PC | 2026-10-03 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-002 | PC | 2026-10-03 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-003 | PC | 2026-10-03 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211479-004 | PC | 2026-10-03 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | Novadoz Pharmaceuticals LLC | 4f890458-be94-4baf-b606-83a097e1e23e | 2026-04-09 | Boxed warning, Warnings, Adverse reactions | 211479 ANDA211479 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 63420 | ORIG | 2020-06-04 |